Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

CV Sciences, Inc. to Present at the 30th Annual ROTH Conference in Dana Point, California, March 11-14, 2018


Posted on: 28 Feb 18

LAS VEGAS, Feb. 28, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (OTCQB:CVSI), preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, announced today that it will be presenting at 30th Annual ROTH Conference. The Conference is being held on March 11-14, 2018 at The Ritz-Carlton in Dana Point, California.

Joseph Dowling, Chief Financial Officer of CV Sciences, will deliver a corporate presentation covering CV Sciences' two distinct business segments: the Company’s industry-leading brand of hemp CBD consumer products distributed to more than 1500 retail stores throughout the U.S.; and, the Company’s drug development business segment, highlighting, CVSI-007, the Company’s lead drug candidate which utilizes synthetically-formulated CBD for use in the treatment of smokeless tobacco addiction. Mr. Dowling will also be conducting one-on-one meetings with investors and analysts.

The 30th Annual ROTH Conference, with close to 550 participating companies and over 4,700 attendees, will feature presentations from public and private companies in a variety of sectors including business services, cleantech, industrial growth & solar, consumer, healthcare, resources: oil & gas / metals & mining, technology, internet & media.

About CV Sciences, Inc.

CV Sciences, Inc (OTCQB:CVSI), located in San Diego, California and Las Vegas, Nevada, focuses on drug development activities on products containing cannabidiol (CBD) as the active pharmaceutical ingredient, and also is engaged in the manufacturing, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand. Additional information is available from OTCMarkets.com or by visiting PlusCBDoil.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

GlobeNewswire
globenewswire.com

Last updated on: 28/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.